RxDoctor Payments Data

Robert Ferguson

Gastroenterology · West Bloomfield, MINPI 1174694673

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 89 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$389
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
  • AbbVie$129
  • Takeda Pharmaceuticals U.S.A., Inc.$107
  • Sanofi$95
  • Ardelyx, Inc.$89
  • plus $368 from 10 others
$1,647in research payments, 2019–2025

Across 3 payments — averaging $549.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Food & beverage$1,34399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,363 in reported general payments places this provider in the 40th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$148,286
Medicare patients
287
Services billed
1,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremasolParenteral Amino Acid 10% No.720$187,986
Humira PenAdalimumab14$153,957
IntralipidFat Emulsions20$90,822
LinzessLinaclotide74$47,906
Ursodiol246$25,155
Pantoprazole Sodium919$15,391
Sucralfate375$15,178
TrulancePlecanatide20$13,283
Mesalamine ErMesalamine52$11,272
Dexlansoprazole DrDexlansoprazole21$11,117
MovantikNaloxegol Oxalate21$10,785
Famotidine720$8,463
Mesalamine DrMesalamine19$7,242
Mesalamine14$6,849
Omeprazole348$6,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$129$47,90674 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$185$13,28320 claims
Braintree Laboratories, Inc.Sutab$54$1,93212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →